Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Divests China Suzhou Site, Antiviral Rights To Fosun

Executive Summary

GSK becomes latest pharma multinational to offload assets in China as competition and pricing pressure continue to mount.

You may also be interested in...



10 Commercial Trends To Watch In China in 2020

2019 will be remembered as a banner year for international drug makers as many grew at phenomenal rates in China, despite expansion of the “4+7” centralized procurement scheme and steep price cuts in exchange for reimbursement. As the government continues to emphasize affordability for cancer drugs and major anti-infectives, competition is heating up quickly and immune-oncology alone has seen six PD-1s elbowing each other for market share.

10 For 2020: Regulatory Trends To Watch In China

2019 was the year that China approved the first new drug for Alzheimer's in nearly two decades and for the first US approval of an original cancer drug from China. While the simmering US trade war has been addressed by a phase one agreement to be signed, other uncertainties marked a year dominated by a large vaccine scandal and resulting bankruptcy, and increasing calls to include China in global clinical development plans.

Love From Shanghai: Upjohn Started Here But Will It Stay Post-Mylan?

Opened with a big splash just two months ago in a brand new headquarters in Shanghai, Pfizer's Upjohn established products subsidiary is now merging with Mylan to create the world's largest generics group, stirring up local concerns that the focus could shift from China back to the US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

WI964858

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel